"Artelo will be able to treat ART27.13 as a normal, non-scheduled investigational medicinal product, which is expected to streamline onboarding of additional clinical sites in the UK, accelerate enrollment of patients, and enhance the commercial potential of ART27.13," said Chief Scientific Officer Andrew Yates.
The pharmaceutical company said it is currently enrolling patients in the UK in a phase 1/2 study to evaluate ART27.13 to treat anorexia in people with cancer. Shares of Artelo Biosciences are up more than 4% in premarket trading.
Price: 0.48, Change: +0.02, Percent Change: +4.37
|MiMedx Says Glass Lewis Recommends in Favor of Direc...|
|T2 Biosystems Says It Secured US Patent Covering Met...|
|TherapeuticsMD Gets FDA Approval for Supplemental Ne...|
|Deere Raises Fiscal 2022 Profit Outlook After Postin...|
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|